Pulse pressure and cardiometabolic disease progression: associations with incident multimorbidity and mortality in UK biobank - Summary - MDSpire

Pulse pressure and cardiometabolic disease progression: associations with incident multimorbidity and mortality in UK biobank

  • By

  • Ting Lin

  • Shuai Hu

  • Wen Gong

  • Linqi Li

  • Zhaowei Zhu

  • Hebin Xie

  • Feijun Zhao

  • June 23, 2026

  • 0 min

Share

Objective:

To investigate the association between pulse pressure (PP) and the progression of cardiometabolic diseases (CMDs), cardiometabolic multimorbidity (CMM), and all-cause mortality.

Approach:
    Key Findings:
    • Per 1-SD increase in PP, there was a significant association with transitions from health to CMD (HR = 1.13, 95% CI: 1.12–1.14) and to CMM (HR = 1.18, 95% CI: 1.15–1.21).
    • Q4 versus Q1 comparisons indicated a 36% higher risk for both CMD and CMM outcomes.
    • The PP–CMM association was strongest among patients with stroke (HR = 1.23, 95% CI: 1.11–1.36) and in participants aged < 60 years, women, and those with BMI 18.5 ≤ 25 kg/m2.
    • Threshold-effect analyses identified specific risk turning points: 40 mmHg for CMD, 42 mmHg for mortality, and 52 mmHg for CMM development.
    Interpretation:

    Elevated pulse pressure is significantly associated with increased risks of cardiometabolic disease progression and mortality.

    Limitations:
    • The study may not account for all potential confounding factors influencing the associations.
    • Findings are based on a specific cohort from the UK Biobank, which may limit generalizability.
    Conclusion:

    Elevated pulse pressure is linked to higher risks of CMD progression and mortality.

Original Source(s)

Related Content